CERo Therapeutics Holdings, Inc.
CERO
$0.8899
-$0.0579-6.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 66.71% | 918.60% | 77.93% | 223.73% | 21.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 86.90% | 186.68% | 113.29% | 86.69% | -12.91% |
| Operating Income | -86.90% | -186.68% | -113.29% | -86.69% | 12.91% |
| Income Before Tax | 153.11% | -213.35% | -17.02% | 5.68% | -558.41% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 153.11% | -213.35% | -17.02% | 5.68% | -381.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 153.11% | -213.35% | -17.02% | 5.68% | -381.61% |
| EBIT | -86.90% | -186.68% | -113.29% | -86.69% | 12.91% |
| EBITDA | -98.60% | -201.96% | -119.02% | -91.06% | -- |
| EPS Basic | 91.61% | 42.80% | 34.53% | 45.02% | -1,521.45% |
| Normalized Basic EPS | 89.47% | 42.80% | 22.57% | 22.29% | -459.64% |
| EPS Diluted | 91.61% | 42.80% | 34.53% | 45.02% | -1,521.45% |
| Normalized Diluted EPS | 89.47% | 42.80% | 22.57% | 22.29% | -459.64% |
| Average Basic Shares Outstanding | 1,888.32% | 447.74% | 78.81% | 28.81% | -70.28% |
| Average Diluted Shares Outstanding | 1,888.32% | 447.74% | 78.81% | 28.81% | -70.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |